Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy

Thymic carcinoma is a rare cancer that is regarded as a model for “major” rare cancers, with several prospective clinical trials aimed at developing pharmacotherapy options having been performed; thus, limited evidence for guidelines based on retrospective studies and single-arm phase II studies with small sample sizes has been accumulated over time [1]. In Ja pan, the number of annual deaths from thymic malignancies was reported to be 418 patients in 2017 [2]. An update of the UICC classification for thoracic malignances, including thymoma and thymic carcinoma, is an ongoing and international challenge that has been underway for the past decade [3].

Source: Lung Cancer - August 19, 2020 Category: Cancer & Oncology Authors: Yusuke Okuma, Ryo Ko, Takeito Shukuya, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Tetsuya Kojima, Yuka Fujita, Toshihiko Hino, Shinsuke Yamanda, Toshiro Suzuki, Aya Fukuizumi, Toshihiro Sakakibara, Toshiyuki Harada, Satoshi Morita Source Type: research